Popular Trials
Popular Filters
Trials for Type 1 Diabetes Patients
Monoclonal Antibodies
Frexalimab + Insulin for Type 1 Diabetes
Recruiting0 awardsPhase 2
Vancouver, British Columbia
This trial is testing a new drug called frexalimab in young people with newly diagnosed Type 1 Diabetes. The goal is to see if it can help their bodies keep making insulin. The study will compare different doses of the drug to find the safest and most effective amount.
Janus Kinase (JAK) Inhibitor
JAK Inhibitors for Type 1 Diabetes
Recruiting0 awardsPhase 2
Aurora, Colorado
This trial is testing two medications, abrocitinib and ritlecitinib, which aim to reduce immune system activity. The study focuses on people who have been recently diagnosed with Stage 3 Type 1 Diabetes. These medications work by calming the immune system to prevent it from attacking insulin-producing cells in the pancreas.
Monoclonal Antibodies
Siplizumab for Type 1 Diabetes
Recruiting1 awardPhase 1 & 2
Birmingham, Alabama
This trial assesses the safety and efficacy of siplizumab in people (8-45 yrs) newly diagnosed w/ Type 1 Diabetes Mellitus (T1DM) over 12 wks, to identify a dosing regimen that induces changes in T cell phenotypes. It also assesses safety profile & effects on residual beta cell function.
Autoantigen-based Therapy
DIAGNODE-3 study for recently diagnosed type I diabetes
Recruiting1 awardPhase 3
Newport Beach, California
This trial tests if using Diamyd and Vitamin D can help young people and adults with Type 1 Diabetes. The goal is to help their bodies keep making insulin for longer. High dose vitamin D and omega 3 have shown promise in prolonging remission in Type 1 Diabetes.
Trials for Diabetes Patients
Monoclonal Antibodies
Frexalimab + Insulin for Type 1 Diabetes
Recruiting0 awardsPhase 2
Vancouver, British Columbia
This trial is testing a new drug called frexalimab in young people with newly diagnosed Type 1 Diabetes. The goal is to see if it can help their bodies keep making insulin. The study will compare different doses of the drug to find the safest and most effective amount.
Janus Kinase (JAK) Inhibitor
JAK Inhibitors for Type 1 Diabetes
Recruiting0 awardsPhase 2
Aurora, Colorado
This trial is testing two medications, abrocitinib and ritlecitinib, which aim to reduce immune system activity. The study focuses on people who have been recently diagnosed with Stage 3 Type 1 Diabetes. These medications work by calming the immune system to prevent it from attacking insulin-producing cells in the pancreas.
Monoclonal Antibodies
Siplizumab for Type 1 Diabetes
Recruiting1 awardPhase 1 & 2
Birmingham, Alabama
This trial assesses the safety and efficacy of siplizumab in people (8-45 yrs) newly diagnosed w/ Type 1 Diabetes Mellitus (T1DM) over 12 wks, to identify a dosing regimen that induces changes in T cell phenotypes. It also assesses safety profile & effects on residual beta cell function.
Monoclonal Antibodies
Rituximab + Abatacept for Type 1 Diabetes
Recruiting0 awardsPhase 2
San Francisco, California
This trial is testing whether a combination of two drugs, rituximab-pvvr followed by abatacept, can better preserve insulin production in people newly diagnosed with Type 1 Diabetes compared to rituximab-pvvr alone. Rituximab-pvvr works by reducing harmful immune cells, while abatacept helps calm the immune system. The goal is to see if this combination can improve insulin production and overall diabetes management.
Trials With No Placebo
Monoclonal Antibodies
Siplizumab for Type 1 Diabetes
Recruiting1 awardPhase 1 & 2
Birmingham, Alabama
This trial assesses the safety and efficacy of siplizumab in people (8-45 yrs) newly diagnosed w/ Type 1 Diabetes Mellitus (T1DM) over 12 wks, to identify a dosing regimen that induces changes in T cell phenotypes. It also assesses safety profile & effects on residual beta cell function.
Stem Cell Therapy
VX-880 for Type 1 Diabetes
Recruiting1 awardPhase 1 & 2
Duarte, California
This trial will test the safety and effectiveness of VX-880 infusion in people with Type 1 diabetes who have trouble sensing low blood sugar and experience severe low blood sugar episodes. The treatment aims to help manage their blood sugar levels better.
Insulin
HDV-Insulin Lispro for Type 1 Diabetes
Recruiting1 awardPhase 2
Atlanta, Georgia
"This trial aims to test if delivering insulin directly to the liver can help improve low blood sugar in Type 1 diabetes patients. Participants will monitor their blood sugar levels using continuous glucose monitoring and work with their
Immunosuppressant
Myfortic for Type 1 Diabetes Islet Transplant Recipients
Recruiting1 award6 criteria
Miami, Florida
This trial is for people who have had a transplant of islet cells (which help produce insulin in the pancreas) that has failed, and now have very low levels of a protein called c-peptide.
Frequently Asked Questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the 'trial drug' — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
Is there any support for travel costs?
Many of the teams running clinical trials will cover the cost of transportation to-and-from their care center.
Will I know what medication I am taking?
This depends on the specific study. If you're worried about receiving a placebo, you can actively filter out these trials using our search.
How long do clinical trials last?
Some trials will only require a single visit, while others will continue until your disease returns. It's fairly common for a trial to last somewhere between 1 and 6 months.
Do you verify all the trials on your website?
All of the trials listed on Power have been formally registered with the US Food and Drug Administration. Beyond this, some trials on Power have been formally 'verified' if the team behind the trial has completed an additional level of verification with our team.
How quickly will I hear back from a clinical trial?
Sadly, this response time can take anywhere from 6 hours to 2 weeks. We're working hard to speed up how quickly you hear back — in general, verified trials respond to patients within a few days.